Clinical profile of gilteritinib in Japanese patients with relapsed/refractory acute myeloid leukemia: An open‐label phase 1 study

Gilteritinib, a novel, highly specific, potent fms‐like tyrosine kinase 3/AXL inhibitor, demonstrated antileukemic activity in patients with relapsed/refractory (R/R) acute myeloid leukemia (AML). In this open‐label phase 1 study (NCT02181660), Japanese patients (aged ≥18 years) with R/R AML receive...

Descripción completa

Detalles Bibliográficos
Autores principales: Usuki, Kensuke, Sakura, Toru, Kobayashi, Yukio, Miyamoto, Toshihiro, Iida, Hiroatsu, Morita, Satoshi, Bahceci, Erkut, Kaneko, Masahito, Kusano, Mikiko, Yamada, Shunsuke, Takeshita, Shigeru, Miyawaki, Shuichi, Naoe, Tomoki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6172068/
https://www.ncbi.nlm.nih.gov/pubmed/30039554
http://dx.doi.org/10.1111/cas.13749

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6172068/
https://www.ncbi.nlm.nih.gov/pubmed/30039554
http://dx.doi.org/10.1111/cas.13749

Ejemplares similares